.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
ScreenPoint Medical Secures $16M to Lead the Next Phase of AI in Breast Cancer Care
ScreenPoint Medical announces $16 million investment from existing partners and research grants to fuel growth and build toward personalized care.
.png)
Explore the future of breast imaging at SBI Symposium 2026
ScreenPoint Medical to present at Society of Breast Imaging Symposium 2026, April 16 to April 19 in Seattle, WA.
.png)
New research examines autonomous AI reading of mammograms
New research from AITIC studies whether AI could safely reduce workload by excluding low-risk exams from radiologist reading.
.png)
ScreenPoint Medical demonstrates Transpara at ECR 2026
Join ScreenPoint Medical at the European Congress of Radiology, March 4-7, 2026 in Vienna, Austria.
.png)
Interview: The Imaging Wire highlights MASAI findings
Brian Casey of The Imaging Wire interviews researcher Jessie Gommers on the latest results from the MASAI randomised controlled trial in breast cancer AI.
.png)
ScreenPoint Medical's founders honored
Nico Karssemeijer and Sir Michael Brady honored for their notable achievements and contributions to healthcare and the sciences.